A5074903501- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Cancer Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Metabolism, Diabetes, and Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Venous Thromboembolism Diagnosis and Management
- Vascular Procedures and Complications
- Intestinal and Peritoneal Adhesions
- Epigenetics and DNA Methylation
- BRCA gene mutations in cancer
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Central Venous Catheters and Hemodialysis
- Hernia repair and management
- Renal and related cancers
- Esophageal and GI Pathology
Medical College of Wisconsin
2014-2023
Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with pancreatic cancer (PC), but its value as treatment biomarker unclear.Although CA19-9 an established PC, it unclear how monitoring should be used to guide multimodality and what level of change in constitutes meaningful response.CA19-9 measurements at diagnosis (pretx), after completion all planned neoadjuvant therapy (preop), surgery (postop) were analyzed localized PC who had elevated (≥35 U/dL) diagnosis. Patients...
Purpose To describe venous thromboembolism (VTE) rates in patients with pancreatic cancer (PC) during neoadjuvant therapy. Methods Factors associated VTE were evaluated using multivariable logistic regression modeling resectable and BLR PC treated therapy between 2009 2014. Results Prevalent VTEs detected 13 (5%) of the 260 patients. Incident 26 (10%); 9 (8%) 109 17 (11%) 151 (P = 0.53). Of incident events, (35%) PEs, extremity DVTs, 8 (31%) involved SMV/PV. catheter-related 7 (27%) Rh(D)...
287 Background: Multiple treatments in series may be difficult for older patients (pt) to tolerate. We sought examine the outcomes associated with neoadjuvant therapy pt resectable (R) or borderline (BLR) pancreatic cancer (PC). Methods: Pt ≥75 years (O) those <75 (Y) R BLR PC receiving from 2008-2012 were identified. Clinicopathologic and treatment data abstracted. Completion of all was defined as receipt followed by surgical resection. Results: identified 77 (42.5%) 104 (57.5%) pt; 29...
Abstract Internal bowel herniation under the ureter of an intraperitoneally transplanted kidney is a rare complication yet carries high burden morbidity and potential mortality if not recognized managed appropriately. We describe case where early intervention salvaged without ureteral injury. also technique to close space beneath prevent further episodes internal herniation.
The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that alone is not sufficient for cure and micrometastases are present even when clinically detected. As such, the delivery early systemic may be a rational alternative to surgery-first approach, in an effort provide oncologic therapies which commensurate disease stage, improve surgical selection. This review details rationale neoadjuvant...